In a report issued on February 24, David Larsen from BTIG maintained a Buy rating on Evolent Health (EVH – Research Report), with a price target of $35.00. The company's shares closed last Wednesday at $29.84. According to TipRanks.com, Larsen 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.5% and a 32.2% success rate. Larsen covers the Technology sector, focusing on stocks such as American Well, Sharecare, and Omnicell. Evolent Health has an analyst consensus of Strong Buy, with a price target consensus of $37.00, implying a 26.7% upside from current levels.
https://www.tipranks.com/news/blurbs/btig-keeps-a-buy-rating-on-evolent-health-evh?utm_source=advfn.com&utm_medium=referral
Evolent Health (NYSE:EVH)
Gráfico Histórico do Ativo
De Mai 2022 até Jun 2022 Click aqui para mais gráficos Evolent Health.
Evolent Health (NYSE:EVH)
Gráfico Histórico do Ativo
De Jun 2021 até Jun 2022 Click aqui para mais gráficos Evolent Health.